Work

Markers of resistance to anti-EGFR therapy in colorectal cancer.

Year: 2013
Type: article
Abstract: Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways.
Authors: Walid Shaib, Reena Mahajan, Bassel El-Rayes
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W1652638408
FWCI: 3.496
Cites: 76
Cited by: 78
Related to: 10